OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Market Closed 12-12 16:00:00 EST

2.06

-0.10

-4.63%

盘后2.02

-0.04-1.90%

19:29 EST

High2.14	Low1.92	Vol179.37K
Open2.14	D1 Closing2.16	Amplitude10.19%
Mkt Cap77.48M	Tradable Cap51.67M	Total Shares37.61M
T/O363.18K	T/O Rate0.72%	Tradable Shares25.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":2.06,"timestamp":1765573200000,"preClose":2.16,"halted":0,"volume":179370,"hourTrading":{"tag":"盘后","latestPrice":2.0208,"preClose":2.06,"latestTime":"19:29 EST","volume":2105,"amount":4231.9778,"timestamp":1765585784239},"delay":0,"floatShares":25081916,"shares":37610676,"eps":-0.119182,"marketStatus":"Market Closed","change":-0.1,"latestTime":"12-12 16:00:00 EST","open":2.14,"high":2.14,"low":1.92,"amount":363180.394035,"amplitude":0.101852,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.119182,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":2.16,"latestTime":"09:12 EST","volume":3358,"amount":7020.2123014,"timestamp":1765548774774},"postHourTrading":{"tag":"盘后","latestPrice":2.0208,"preClose":2.06,"latestTime":"19:29 EST","volume":2105,"amount":4231.9778,"timestamp":1765585784239},"volumeRatio":0.7928196722266551},"requestUrl":"/m/hq/s/OKYO/wiki","defaultTab":"wiki","newsList":[{"id":"2590519388","title":"OKYO Pharma Reports Phase 2 Trial Shows Urcosimod Improves Corneal Nerve Health in Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2590519388","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590519388?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:30","pubTimestamp":1765459832,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. has announced new data from its Phase 2 clinical trial evaluating urcosimod for the treatment of neuropathic corneal pain . The placebo-controlled, randomized, double-masked study found that patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in both corneal nerve fiber count and nerve fiber length, as measured by in vivo confocal microscopy. These trends were not observed in the placebo group. The results, which have already been analyzed, suggest that urcosimod may have a positive impact on corneal nerve structure in patients with NCP.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3FNtQm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","OKYO","LU2210149790.SGD","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2589562363","title":"OKYO Pharma Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2589562363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589562363?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:09","pubTimestamp":1765202940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 09:09 ET (14:09 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","OKYO","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4139","RILY","IE0031619046.USD","BK4127"],"gpt_icon":0},{"id":"2589461330","title":"B. Riley Initiates Coverage on OKYO Pharma With Buy Rating, $5 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589461330","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589461330?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:23","pubTimestamp":1765196607,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) has an average rating of Buy and mean price target of $6, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RILY","OKYO"],"gpt_icon":0},{"id":"2588204346","title":"OKYO Pharma Chairman Gabriele Cerrone Acquires Additional 27,051 Company Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588204346","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588204346?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763221,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. announced that Panetta Partners Limited, an entity in which Executive Chairman and founder Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares of the company on NASDAQ. This transaction increases Cerrone's total holding to 10,491,746 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL5B5Kx2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","OKYO","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2588454840","title":"OKYO Pharma Announces Chairman and Founder Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588454840","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588454840?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763200,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198742/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2586505642","title":"OKYO Pharma Ltd. Announces Date for Upcoming Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586505642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586505642?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:46","pubTimestamp":1764164781,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. has announced that its Annual General Meeting will be held virtually on 16 December 2025. Shareholders will be asked to vote on a series of resolutions that are regularly brought before the company, as recommended by the Board. The results of the meeting will be posted on the company's website on the day of the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL93J8mV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2585456431","title":"OKYO Pharma Chairman Gabriele Cerrone Acquires Additional 82,018 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585456431","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585456431?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:30","pubTimestamp":1763731814,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. announced that Panetta Partners Limited, an entity in which Executive Chairman and Founder Gabriele Cerrone has a beneficial interest, has acquired 82,018 of the company's ordinary shares on NASDAQ. This purchase increases Cerrone's total holding to 10,464,695 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL7m0Vl6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","OKYO","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","BK4585","IE00B64PRP62.GBP","NDAQ","BK4588","LU2210149790.SGD","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2585145779","title":"OKYO Pharma Announces Chairman and Founder Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145779","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145779?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:30","pubTimestamp":1763731800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Nov.  21, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/21/3192792/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","TQQQ",".IXIC","OKYO","PSQ","QID","USJW.SI","BK4139","USAW.SI","QLD","SQQQ","NVIW.SI","MNQmain","NQmain"],"gpt_icon":1},{"id":"2584958267","title":"OKYO Pharma to Present Urcosimod at OIS XV","url":"https://stock-news.laohu8.com/highlight/detail?id=2584958267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584958267?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:58","pubTimestamp":1763474285,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On November 18, 2025, OKYO Pharma Limited announced that its CEO, Gary S. Jacob...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-urcosimod-at-ois-xv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-urcosimod-at-ois-xv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4179","BK4139","OIS","XV","OKYO"],"gpt_icon":0},{"id":"2584930793","title":"OKYO Pharma to Present at Ophthalmology Innovation Summit in San Diego","url":"https://stock-news.laohu8.com/highlight/detail?id=2584930793","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584930793?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:30","pubTimestamp":1763472656,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. will present at the Ophthalmology Innovation Summit XV in San Diego, taking place November 21-22, 2025. The company will showcase its lead investigational drug candidate, urcosimod, developed to treat neuropathic corneal pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1vchfW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2579749249","title":"OKYO Pharma to Present at BIO-Europe in Vienna","url":"https://stock-news.laohu8.com/highlight/detail?id=2579749249","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579749249?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:01","pubTimestamp":1761735695,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. will attend the 33rd Annual BIO-Europe partnering conference in Vienna, Austria, scheduled for November 3-5, 2025. The company will present updates on its lead investigational candidate, urcosimod, including results from a recently completed Phase 2 clinical trial for the treatment of neuropathic corneal pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDLs1T8d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","OKYO","BK4585","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD"],"gpt_icon":0},{"id":"2575557741","title":"OKYO Pharma’s Chairman Increases Stake with New Share Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2575557741","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575557741?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:57","pubTimestamp":1760619448,"startTime":"0","endTime":"0","summary":"An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On October 16, 2025, OKYO Pharma Limited announced that Panett...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-chairman-increases-stake-with-new-share-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-chairman-increases-stake-with-new-share-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2575774643","title":"OKYO Pharma Chairman Gabriele Cerrone Acquires Additional 210,000 Shares, Increases Total Holding to 10,382,677","url":"https://stock-news.laohu8.com/highlight/detail?id=2575774643","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575774643?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:31","pubTimestamp":1760617899,"startTime":"0","endTime":"0","summary":"Panetta Partners Limited, an entity in which OKYO Pharma Ltd. Executive Chairman Gabriele Cerrone has a beneficial interest, has acquired 210,000 ordinary shares of OKYO Pharma on NASDAQ. This brings Cerrone's total holding to 10,382,677 shares. The price of the transaction was not disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL3rpnqp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2575749350","title":"OKYO Pharma Announces Chairman and Founder Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575749350","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575749350?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:30","pubTimestamp":1760617800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Oct.  16, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167912/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","TQQQ","QLD","MNQmain","SQQQ","USJW.SI","QID","NVIW.SI","USAW.SI",".IXIC","BK4139","PSQ","TSYW.SI","NQmain"],"gpt_icon":1},{"id":"2569791077","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2569791077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569791077?lang=en_us&edition=fundamental","pubTime":"2025-09-23 18:52","pubTimestamp":1758624720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 23, 2025 06:52 ET (10:52 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2569791426","title":"Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD) and OKYO Pharma Limited Sponsored ADR (OKYO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569791426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569791426?lang=en_us&edition=fundamental","pubTime":"2025-09-23 18:30","pubTimestamp":1758623415,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mind Medicine (MNMD – Research Report) and OKYO Phar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mind-medicine-mnmd-and-okyo-pharma-limited-sponsored-adr-okyo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mind-medicine-mnmd-and-okyo-pharma-limited-sponsored-adr-okyo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4581","BK4007","BK4139","BK4137","XBI","XLV","HCSG","MNMD","OKYO","LABU","BK4547"],"gpt_icon":0},{"id":"2569782123","title":"Okyo Pharma announces plans for next stage of development for urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2569782123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569782123?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:40","pubTimestamp":1758544825,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-announces-plans-for-next-stage-of-development-for-urcosimod-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-announces-plans-for-next-stage-of-development-for-urcosimod-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2569278257","title":"OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2569278257","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569278257?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:30","pubTimestamp":1758544200,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Sept.  22, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153922/0/en/OKYO-Pharma-Announces-Registration-Pathway-with-100-Patient-Multi-Center-Clinical-Trial-of-Urcosimod-in-Neuropathic-Corneal-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2559362126","title":"OKYO Pharma Ltd. Files Amendment to Annual Report on Form 20-F/A for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559362126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559362126?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:30","pubTimestamp":1755030649,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. filed an amendment to the 10-K annual report for the financial year ended March 31, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1YgWst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2552490899","title":"OKYO Pharma Reports No Revenue from Product Sales for Fiscal Year Ending March 31, 2025; Continues to Anticipate Future Revenue Post Regulatory Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2552490899","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552490899?lang=en_us&edition=fundamental","pubTime":"2025-07-19 04:32","pubTimestamp":1752870722,"startTime":"0","endTime":"0","summary":"OKYO Pharma Reports No Revenue from Product Sales for Fiscal Year Ending March 31, 2025; Continues to Anticipate Future Revenue Post Regulatory Approvals. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL5CKbgs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":0.0785},{"period":"1month","weight":-0.2077},{"period":"3month","weight":-0.0419},{"period":"6month","weight":-0.3156},{"period":"1year","weight":0.9434},{"period":"ytd","weight":0.7915}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.025783},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.009282},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.03944},{"month":4,"riseRate":0.666667,"avgChangeRate":0.001581},{"month":5,"riseRate":0.666667,"avgChangeRate":0.132873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013367},{"month":7,"riseRate":1,"avgChangeRate":0.208942},{"month":8,"riseRate":0.5,"avgChangeRate":0.008913},{"month":9,"riseRate":0.25,"avgChangeRate":-0.093671},{"month":10,"riseRate":0.5,"avgChangeRate":0.07182},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.058065}],"exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction